胃肠道来源脑转移瘤放疗的临床结局
SRS与WBRT的总生存无显著差异(p=0.424),但WBRT的新发部位控制显著优于SRS(p=0.017)。总体生存和颅内疾病控制均较差,提示需探索局部控制改进方法。
要点
- SRS与WBRT总生存无显著差异(p=0.424),中位OS分别为5.2个月和4.4个月。
- WBRT新发部位控制显著优于SRS(p=0.017), crude新发控制率分别为83.3%和46.4%。
- 多因素分析中总剂量、WBRT和活动性颅外疾病与新发部位控制显著相关(p<0.05)。
核心结论
- 胃肠道原发脑转移放疗后生存和颅内疾病控制均较差,结局劣于其他原发恶性肿瘤脑转移的已发表系列。
- SRS与WBRT总生存无统计学显著差异,但WBRT新发部位控制显著更优。
研究设计与样本
- 患者接受立体定向放射外科(SRS)或全脑放疗(WBRT),采用Kaplan-Meier法计算初始部位控制、新发部位控制和总生存。
主要发现
- 原发恶性肿瘤部位:结肠18例、食管6例、直肠4例、其他5例。
- SRS中位总剂量25 Gy(18-35 Gy),中位4次;WBRT中位总剂量30 Gy(10.8-40 Gy),10次。
- 末次影像随访时粗初始部位控制率:SRS后64.3%,WBRT后41.7%。
- 末次影像随访时粗新发部位控制率:SRS后46.4%,WBRT后83.3%。
- SRS患者中位总生存5.2个月(0.5-57.5),WBRT患者4.4个月(0-15),Kaplan-Meier分析无统计学显著差异(p=0.424)。
关键数值与推荐
- Kaplan-Meier分析显示WBRT较SRS显著改善新发部位控制(p=0.017)。
- 多因素分析中总剂量、WBRT和活动性颅外疾病对新发部位控制有统计学显著性(p<0.05)。
临床怎么用
- 对于胃肠道原发脑转移,SRS和WBRT均可考虑,但需告知患者生存和颅内控制均较差。
- WBRT可能有助于改善新发部位控制,SRS局部初始控制率数值较高但新发控制较差。
- 未来研究可探索剂量递增或放射增敏以改善该人群局部控制。
局限性
- 部分病灶在放疗前接受切除,可能影响控制率评估。
- 作者指出该系列样本量小,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brain metastases of gastrointestinal origin are a rare occurrence. Radiation therapy (RT) in the form of stereotactic radiosurgery (SRS) or whole brain radiation therapy (WBRT) is an effective established treatment modality in either the definitive or adjuvant setting. The aim of this study is to assess the long-term clinical outcomes of patients with gastrointestinal (GI) brain metastases treated with SRS or WBRT. METHODS: In this single institutional retrospective review, we detail the outcomes of patients diagnosed with metastatic brain tumors from an adenocarcinoma gastrointestinal primary. Patients were treated using stereotactic radiosurgery or whole brain radiation therapy. Initial site control (defined as lesions visualized on imaging at time of treatment), new site control (defined as new intracranial lesions visualized on follow-up imaging), and overall survival were calculated using the Kaplan-Meier method. RESULTS: Thirty-three patients were treated from August 2008 to December 2015. Primary malignancy locations were as follows: 18 colon, 6 esophagus, 4 rectum, 5 other. Median total dose delivered was 25 Gy (18-35 Gy) in a median of 4 fractions for SRS and 30 Gy (10.8-40 Gy) in 10 fractions for WBRT. Crude initial site control at last radiographic follow-up was 64.3% after SRS and 41.7% after WBRT. Eleven of the 28 brain lesions (39.3%) treated with SRS had resection of the SRS-treated lesion prior to radiation therapy. Five of the twelve patients (41.7%) undergoing WBRT underwent cranial resection prior to radiation therapy. Crude new site control at last radiographic follow-up was 46.4% after SRS and 83.3% after WBRT. Kaplan-Meier analysis of overall survival did not show any statistically significant difference between WBRT and SRS (p = 0.424). Median overall survival for SRS patients was 5.2 months (0.5-57.5) and for WBRT patients 4.4 months (0-15). Kaplan-Meier analysis of new site control was significantly improved with WBRT versus SRS (p = 0.017). Total dose, treatment with WBRT, and active extracranial disease were statistically significant on multivariate analysis for new site control (p < 0.05). CONCLUSIONS: Survival and intracranial disease control are poor following RT for brain metastases from GI primaries. In this small series, outcomes are worse than published series for other primary malignancies metastatic to the brain and further research into methods of local control improvement is warranted. Future studies should explore the utility of dose escalation or radiosensitization in this patient population.
引用
- Sanghvi SM, Lischalk JW, Cai L, et al. Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy. Radiat Oncol. 2017. PMID: 28245881. doi:10.1186/s13014-017-0774-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。